U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-QSB/A
(Mark One)
|X| QUARTERLY REPORT PURSUANT SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 1999
TRANSITION REPORT PURSUANT SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____ to ____
Commission File Number 0-26775
STEROIDOGENESIS INHIBITORS INTERNATIONAL, INC.
----------------------------------------------
(Exact name of small business issuer as specified in its charter)
NEVADA 88-0384037
------------------------------- --------------
(State or other jurisdiction of (IRS. Employer
incorporation or organization) Identification No.)
101 Convention Center Dr. Suite 310 89109
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Issuer's telephone number: 702-735-7001
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes |_| No |X|
The number of shares of Common Stock outstanding as at November 19, 1999 was
15,136,979.
Transitional Small Business Disclosure Format (check one): Yes |_| No |X|
1
<PAGE>
PART I-FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS.
The information required is attached.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYIS OR PLAN OF OPERATION.
The Issuer has no revenues to report for the period covered by this Report nor
any material revenues for the past two years, and relies upon services rendered
by key personnel, often unpaid with compensation to be addressed in the future,
and financial sources, on an intermittent basis, such as private investment
funding. The Issuer has been incurring expenditures to primarily operate or
administer its business, including general working capital such as rent,
payroll, and professional fees, and more importantly to pursue its business
plan, certain portions of which are summarized herein.
The Issuer is continuing a plan, which may continue for the next 12 months or
more or less depending upon its success, and modifications by Management and
factors beyond control of the Issuer (such as the results and impact of
independent testing), to aggressively pursue the completion of the testing,
manufacturing, marketing and sale of its proprietary product, or future
products, currently developed and as formulated in the months ahead, including
the ANTICORT (TM) drug.
This plan is contingent upon various factors, including obtaining necessary FDA
approvals and other governmental authorizations as may be necessary domestically
and overseas wherever the product or products are sought to be manufactured and
sold. The plan's current emphasis is upon commercial introduction of ANTICORT
into the market place as a viable, FDA approved product. The Issuer is
establishing strategic alliances and relationships, and is seeking to confirm
these under contracts, covering various business pursuits relating to its plan,
including final research and testing of the product, funding, and contract
manufacturing and sale. Revenues are not anticipated for the next quarter, and
no assurance exists that the foregoing plan will be effective or achieved.
2
<PAGE>
PART II-OTHER INFORMATION
ITEM 5. OTHER INFORMATION.
The Issuer intends to respond to comments from the Commission as to it recent
Form 10-SB filing and file an amendment as advised by counsel.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
a. Exhibits Index - FORM 10-QSB.
3 (i) Articles of Incorporation (*)
(ii) Bylaws (*)
*Incorporated herein by reference to the Issuer Form 10-SB filing, as may
be amended from time to time, on file with the Commission.
b. Reports on Form 8-K. No Reports were filed for the last quarter of the fiscal
year covered by this report
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
STEROIDOGENESIS INHIBITORS INTERNATIONAL, INC.
(Registrant)
By: /s/ Alfred T. Sapse,
President
(principal executive officer)
Date: 12/17/99
3
